Novartis India Limited

NSEI:NOVARTIND Stock Report

Market Cap: ₹22.6b

Novartis India Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Sanjay Murdeshwar

Chief executive officer

₹10.1m

Total compensation

CEO salary percentage64.6%
CEO tenure4.6yrs
CEO ownershipn/a
Management average tenure3.2yrs
Board average tenure7.8yrs

Recent management updates

Recent updates

Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio

Apr 04
Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio

Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock

Jan 29
Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock

Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?

Jan 02
Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?

Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing

Dec 07
Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing

We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability

Nov 08
We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability

Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?

Oct 11
Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?

CEO Compensation Analysis

How has Sanjay Murdeshwar's remuneration changed compared to Novartis India's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

₹766m

Jun 30 2023n/an/a

₹712m

Mar 31 2023₹10m₹7m

₹1b

Dec 31 2022n/an/a

₹550m

Sep 30 2022n/an/a

₹537m

Jun 30 2022n/an/a

₹424m

Mar 31 2022₹7m₹7m

-₹37m

Dec 31 2021n/an/a

₹294m

Sep 30 2021n/an/a

₹223m

Jun 30 2021n/an/a

₹228m

Mar 31 2021₹7m₹7m

₹209m

Dec 31 2020n/an/a

₹180m

Sep 30 2020n/an/a

₹264m

Jun 30 2020n/an/a

₹137m

Mar 31 2020₹9m₹7m

₹101m

Compensation vs Market: Sanjay's total compensation ($USD121.39K) is below average for companies of similar size in the Indian market ($USD188.08K).

Compensation vs Earnings: Sanjay's compensation has increased by more than 20% in the past year.

CEO

Sanjay Murdeshwar (57 yo)

4.6yrs

Tenure

₹10,090,000

Compensation

Mr. Sanjay Prabhakar Murdeshwar serves as Vice Chairman and Managing Director at Novartis India Limited since June 15, 2019. Mr. Murdeshwar served as Managing Director of AstraZeneca Pharma India Limited s...

Leadership Team

NamePositionTenureCompensationOwnership
Sanjay Murdeshwar
MD & Vice Chairman4.6yrs₹10.09mno data
Shilpa Joshi
CFO & Whole-Time Director1.7yrs₹3.92mno data
Nikhil Malpani
Company Secretary & Compliance Officer1.8yrsno datano data
Vasant Narasimhan
Chief Executive Officer of Novartis5.9yrsno datano data

3.2yrs

Average Tenure

Experienced Management: NOVARTIND's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sanjay Murdeshwar
MD & Vice Chairman4.6yrs₹10.09mno data
Shilpa Joshi
CFO & Whole-Time Directorno data₹3.92mno data
Jai Hiremath
Independent Director18yrs₹1.00mno data
Sanker Parameswaran
Independent Non-Executive Director3.6yrs₹1.00mno data
Christopher Snook
Non-Executive Chairman15.4yrsno datano data
Sandra Martyres
Independent Non-Executive Director7.8yrs₹1.00mno data

7.8yrs

Average Tenure

69yo

Average Age

Experienced Board: NOVARTIND's board of directors are considered experienced (7.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/22 13:50
End of Day Share Price 2023/10/25 00:00
Earnings2023/09/30
Annual Earnings2023/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novartis India Limited is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Amit GuptaBatlivala & Karani Securities India Pvt. Ltd.
Anil BurraFirstCall Research
Suhani AdilabadkarFirstCall Research